<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57048">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934933</url>
  </required_header>
  <id_info>
    <org_study_id>[2013]2-93</org_study_id>
    <nct_id>NCT01934933</nct_id>
  </id_info>
  <brief_title>Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis</brief_title>
  <official_title>An Open Clinical Trial to Assess Efficacy for Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label trial to evaluate efficacy for delaying ossification and
      improving inflammation of celebrex treatment on active ankylosing spondylitis (AS). Subjects
      will be randomly divided into three groups (Enbrel group, Celebrex group and Enbrel plus
      Celebrex group) and receive responsable treatment for 54 weeks. Clinical response
      assessment, laboratory assessment and radiology assessment will be recorded. Primary
      endpoints are the magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of
      Canada (SPARCC) score and the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) of
      spine and sacroiliac(SI) joint, as well as the Assessment of SpondyloArthritis International
      Society (ASAS)20 response rate. Secondary Endpoints include ASAS20, ASAS40, ASAS70 and
      ASAS5/6 response rate on each visit and other clinical indexes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the SPARCC score of spine and SI joint</measure>
    <time_frame>24th weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the MRI SPARCC score of spine and SI joint on 24th week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mSASSS score of spine</measure>
    <time_frame>52th week</time_frame>
    <safety_issue>No</safety_issue>
    <description>the mSASSS score of spine on 52th week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASAS20 response rate</measure>
    <time_frame>24th week</time_frame>
    <safety_issue>No</safety_issue>
    <description>ASAS20 response rate on 24th week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASAS20 response</measure>
    <time_frame>24th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS40 response</measure>
    <time_frame>24th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS70 response</measure>
    <time_frame>24th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS5/6 response</measure>
    <time_frame>24th week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Inflammation</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celebrex capsule, 0.2 gram bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept injection, 25mg per injection,50mg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celebrex</intervention_name>
    <arm_group_label>celebrex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <arm_group_label>Enbrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel plus Celebrex</intervention_name>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years

          -  Meet 1984 NewYork modified criteria for AS

          -  BASDAI≥4 or ASDAS score ≥ 2.1

          -  CRP＞6 mg/L or ESR＞28 mm/h

          -  Syndesmophyte quantity ≥2 and ＜16 of spine

          -  Sexually active women of childbearing potential must agree and commit to use a
             medically accepted form of contraception

          -  No active or latent tuberculosis infection.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  current or previous history of psoriasis or inflammatory bowel disease.

          -  infection with clinical significance within 24 weeks before screening

          -  receipt any bio-agents treatment within 12 weeks before screening

          -  corticosteroids intra-articular injections in last 3 months before the trial

          -  Significant concurrent medical events including: Gastrointestinal ulcer, myocardial
             infarction within 12 months before the screening visit, unstable angina pectoris,
             congestive heart failure.

          -  Alcohol and drug abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jieruo Gu, Prof</last_name>
    <phone>+8620-85252055</phone>
    <email>gujieruo@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieruo Gu, Prof</last_name>
      <phone>+8620-85252055</phone>
      <email>gujieruo@163.com</email>
    </contact>
    <investigator>
      <last_name>Jieruo Gu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gu Jieruo</investigator_full_name>
    <investigator_title>Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>ossification</keyword>
  <keyword>etanercept</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
